<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10408846</article-id><article-id pub-id-type="pmc">2362330</article-id><article-id pub-id-type="pii">6690371</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690371</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Pretreatment serum markers and lymphocyte response to interleukin-2 therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fumagalli</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lissoni</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Felice</surname><given-names>G Di</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meregalli</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Valsuani</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mengo</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rovelli</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">3</xref></contrib><aff id="aff1">Chiron Italia, Milano, Italy</aff><aff id="aff2">Division of Radiation Oncology, andLaboratory, S Gerardo Hospital, 20052 Monza (Milano), Italy</aff></contrib-group><pub-date pub-type="ppub"><month>5</month><year>1999</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>1999</year></pub-date><volume>80</volume><issue>3-4</issue><fpage>407</fpage><lpage>411</lpage><history><date date-type="received"><day>19</day><month>05</month><year>1998</year></date><date date-type="rev-recd"><day>27</day><month>10</month><year>1998</year></date><date date-type="accepted"><day>19</day><month>11</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Lymphocytosis is a marker of subcutaneous interleukin (IL)-2 therapy efficacy, whereas baseline elevated inflammatory indices were noticed in IL-2-resistant disease. The aim of this study was to analyse the relationship between pretreatment circulating values of IL-6, neopterin, sIL-2R, ESR and the changes in lymphocyte number in response to IL-2 administration. Twenty metastatic renal cell cancer patients were treated with subcutaneous IL-2 immunotherapy (6 000 000 IU day<sup>&#x02212;1</sup> for 6 days per week for 4 weeks); tumour response consisted of partial response (PR) in four patients, stable disease (SD) in eight patients and progressive disease (PD) in eight patients. Abnormally high pretreatment values of each marker were found as follows: IL-6 in seven patients, neopterin in nine patients, sIL-2R in 13 patients. In response to IL-2 immunotherapy, a significantly higher mean increase in lymphocyte number and a higher percentage of patients with tumour response or stable disease were observed when pretreatment values of IL-6, neopterin and sIL-2R were within the normal range, in comparison to patients with high values for these markers. The pretreatment excess of these serum inflammatory markers seems to negatively influence both the host and tumour response to IL-2 administration, by preventing the IL-2-induced lymphocytosis and resulting in tumour progression. Further studies are requested to verify if overall survival and quality of life may depend on pretreatment host immune status and/or lymphocyte response after IL-2 administration. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>IL-2</kwd><kwd>immunotherapy</kwd><kwd>IL-6</kwd><kwd>neopterin</kwd><kwd>sIL-2R</kwd><kwd>lymphocytosis</kwd></kwd-group></article-meta></front></article>
